EU Clinical Trial 2017-002154-36

A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Severe Japanese Cedar Pollinosis Despite the Current Recommended Therapies  Feb 13, 2019

Main objective of the trial: To demonstrate the efficacy of omalizumab compared with placebo

Parties

Sponsors
Countries
JP
Keywords
IGE025 OMALIZUMAB Pollinosis Respiratory, thoracic and mediastinal disorders Xolair

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.